

RESEARCH LETTER

Blood Oxygen Level Dependent Magnetic Resonance Imaging To Predict Split Renal Function Improvement After Renal Artery Stenting

Zhiyong Lin ^{b,†}, Bihui Zhang ^{a,†}, Letao Lin ^{a,c,d,†}, Yinghua Zou ^a, Jianxing Qiu ^{b,i,**}, Min Yang ^{a,*}

^a Department of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing, China

^b Department of Radiology, Peking University First Hospital, Beijing, China

^c State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University Cancer Centre, Guangzhou, Guangdong, China

^d Minimally Invasive Interventional Division, Sun Yat-sen University Cancer Centre, Guangzhou, Guangdong, China

Atherosclerotic renal artery stenosis (ARAS) is the most common cause of secondary hypertension.¹ Renal artery stenting (RAS) is the first line revascularisation option with a high technical success rate, but the clinical response rate is indeterminate.² Blood oxygen level dependent magnetic resonance imaging (BOLD-MRI) is a non-invasive imaging technique that can assess the kidney's oxygenation.³ It uses endogenous deoxygenated haemoglobin as a contrast agent and detects magnetic field disturbances caused by changes of oxygenated haemoglobin.³ The R2* score correlates positively with deoxyhaemoglobin levels and can evaluate the severity of ischaemia caused by ARAS.^{4,5} A normally perfused kidney has a low R2* score in the cortex and a higher R2* score in the deeper medullary region, which is consistent with the gradient of hypoxia in deep medullary regions. A low R2* score is observed if there is adequate perfusion and tissue function, but can also be seen if the kidney is non-functioning as the oxygenated blood passes through without oxygen utilisation or consumption by atrophic tissue.^{3,4} High R2* appears when there is a substantial decrease in renal blood flow and the kidney remains salvageable, which is exactly the situation in which patients with ARAS may benefit from RAS. This study aimed to investigate the feasibility and accuracy of BOLD-MRI in predicting split renal function (SRF) improvement after RAS in patients with ARAS.

Patients with severe ARAS were enrolled consecutively between 1 May 2018 and 30 November 2018. Symptomatic patients were enrolled if the ARAS caused hypertension, impaired renal function, acute pulmonary oedema, or unstable angina pectoris. Patients whose renal artery stenosis was caused by non-atherosclerotic factors, with severe renal dysfunction (serum creatinine > 3.0 mg/dL), or atrophied kidney (length < 7 cm) were excluded.

For the patients with severe stenoses or occlusions, RAS was performed. All BOLD-MRI examinations were performed with a MAGNETOM Aera 1.5T MR scanner (Siemens

Healthcare GmbH, Erlangen, Germany). Four regions of interest were traced: one on the cortex and three on the upper, middle, and lower poles of the medulla (Fig. 1A). The T2* values of the BOLD-MRI images were measured and converted into R2* values according to the formula: $R2^* = 1/T2^*$. Clinical follow up visits were scheduled one month after discharge from the outpatient department. SRF was evaluated by nuclear renal dynamic imaging at baseline and follow up. Change of glomerular filtration rate (GFR) was defined as the difference between the GFR taken at the one month follow up and the baseline GFR. SRF improvement of the affected kidney was defined when the change in GFR was $\geq 15\%$ of the baseline GFR. The antihypertensive drugs were not altered after RAS.

Pearson correlation coefficient was used to evaluate the correlation between R2* and change of GFR. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the performance of baseline cortical and medullary R2*. The area under the curve (AUC) was used to evaluate the overall accuracy.

Thirty patients with ARAS were included in this study and nine patients had bilateral lesions. The average age was 64 ± 9 years, and 73% of patients were male. All patients suffered from high blood pressure. Overall, 35 renal arteries were treated successfully with stents. Four renal artery occlusions were not treated successfully.

All patients completed a one month clinical follow up. The average systolic and diastolic blood pressure decreased (systolic: 161 ± 20 mmHg vs. 133 ± 11 mmHg, diastolic: 88 ± 12 mmHg vs. 78 ± 9 mmHg, both $p < .001$). No in-stent restenosis was found. The estimated GFR value was calculated for each patient. The average eGFR was 52.64 ± 18.72 mL/min/1.73 m² at baseline and 53.39 ± 17.16 mL/min/1.73 m² at one month follow up. One patient did not complete the nuclear renal dynamic imaging. SRF improvement occurred in 19/34 of the stented kidneys in 17/29 of patients. There was a moderate


[†] Equal contribution.

* Corresponding author. Department of Interventional Radiology and Vascular Surgery, Peking University First Hospital, No.8, Xishiku Street, Xicheng District, Beijing, 100000, China.

** Corresponding author.

E-mail address: qx761225@126.com (Jianxing Qiu); dryangmin@gmail.com (Min Yang).

[†] Department of Radiology, Peking University First Hospital, No.8, Xishiku Street, Xicheng District, Beijing, 100000, China.



positive correlation between the GFR change and baseline cortical R2* value ($r = 0.67$; $p < .001$) and medullary R2* value ($r = 0.48$; $p = .004$). The baseline cortical and medullary R2* in the SRF improvement group ($14 \pm 2 \text{ s}^{-1}$ and $29 \pm 3 \text{ s}^{-1}$, respectively) were higher (both $p < .001$) than those in the non-improvement group ($12 \pm 1 \text{ s}^{-1}$ and $25 \pm 3 \text{ s}^{-1}$, respectively). For patients with SRF improvement, the serum creatinine level did not decrease ($p = .340$). The ROC curves of cortical R2* and medullary R2* are shown in Fig. 1B. The AUC of medullary R2* was 0.86 (95% CI 0.74 – 0.99), which was larger than that of cortical R2* (0.73, 95% CI 0.55 – 0.90), indicating that medullary R2* was more accurate and may be a better predictor. The cutoff value of baseline medullary R2* was 23.7 s^{-1} , the sensitivity was 0.95 (95% CI 0.74 – 1.00), and the specificity was 0.67 (95% CI 0.38 – 0.88).

The limitations of the present study included small sample size, limited follow up time, and single centre experience.

BOLD-MRI may identify patients with severe ARAS whose SRF could benefit from RAS. This study found that medullary R2* $\geq 23.7 \text{ s}^{-1}$ had good sensitivity and moderate specificity, making this a promising predictor of SRF improvement after RAS.

CONFLICT OF INTEREST

None.

FUNDING

This study was supported by National Key R&D Program of China (grant No.2017YFC0109105), the Scientific Research Seed Fund of Peking University First Hospital (grant

No.2018SF023), Youth clinical research project of Peking University First Hospital (grant No.2018CR16), and Interdisciplinary clinical research project of Peking University First Hospital (grant No.2018CR33).

REFERENCES

- Hansen KJ, Edwards MS, Craven TE, Cherr GS, Jackson SA, Appel RG, et al. Prevalence of renovascular disease in the elderly: a population-based study. *J Vasc Surg* 2002;36:443–51.
- Prince M, Tafur JD, White CJ. When and how should we revascularize patients with atherosclerotic renal artery stenosis? *JACC Cardiovasc Interv* 2019;12:505–17.
- Textor SC, Glockner JF, Lerman LO, Misra S, McKusick MA, Riederer SJ, et al. The use of magnetic resonance to evaluate tissue oxygenation in renal artery stenosis. *J Am Soc Nephrol* 2008;19:780–8.
- Manohar S, Hamadah A, Herrmann SM, Textor SC. Total renal artery occlusion: recovery of function after revascularization. *Am J Kidney Dis* 2018;71:748–53.
- Saad A, Herrmann SM, Crane J, Glockner JF, McKusick MA, Misra S, et al. Stent revascularization restores cortical blood flow and reverses tissue hypoxia in atherosclerotic renal artery stenosis but fails to reverse inflammatory pathways or glomerular filtration rate. *Circ Cardiovasc Interv* 2013;6:428–35.

Keywords:

Atherosclerotic renal artery stenosis, Blood oxygen level dependent magnetic resonance imaging, Prediction, Renal artery stenting

Available online 10 March 2022

© 2022 Published by Elsevier B.V. on behalf of European Society for Vascular Surgery.

<https://doi.org/10.1016/j.ejvs.2021.12.044>